VECT News and Press, VectivBio Holding AG From 04/19/23

Continued Strong Progress and Momentum Across Multiple Programs with Key Upcoming Data Milestones Beginning Q2 2023 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) to Complete Enrollment this Quarter Interim Results of STARGAZE P...

2023-04-17 08:00:00 ET Summary VectivBio Holding AG has strong data in rare disease, and the data is better than those from the only approved competitor. They have a long cash runway. Pivotal data is due in H2 2023. For further details see: VectivBio:...

BASEL, Switzerland, April 12, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced they will report financial results for the fu...

BASEL, Switzerland, March 13, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, and Asahi Kasei Pharma Corporation (“Asahi Kasei Pharm...

VectivBio Holdings ( NASDAQ: VECT ) has filed for a $350M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for pipeline development, general corporate purposes, and worki...

Summary There could be bargains among the biotechs listed in the US. VectivBio Holding AG could be a bargain. This biotech develops a treatment that could make a valuable contribution to improving the quality of life of patients with certain bowel disorders. VectivBio Holding is on ...

Jefferies has initiated VectivBio ( NASDAQ: VECT ) with a buy saying that its GLP2 candidate apraglutide "could revolutionize short bowel syndrome-intestinal failure (SBS- IF) by achieving/accelerating independence from IV nutrition." The firm has an $18 price target (115% upside base...

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the Extraordinary Gene...

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Found...

-Largest global Phase 3 study ever conducted in SBS-IF recruiting a total of 144 patients, stratified 50/50 for Stoma and CIC anatomical subtypes -First Phase 3 study to prospectively evaluate safety and efficacy of a GLP-2 agonist in SBS-IF according to patient’s remnant...